Suven Life Sciences Limited has reported a net profit of Rs 3.36 crore for the quarter ended June 30, 2011, up marginally from Rs 3.44 crore in the corresponding quarter of last fiscal.
The company revenues stood at Rs 44.84 crore (Rs 36.31 crore) a 23.48 per cent growth for the quarter under review. A highlight of the quarter was the continued spending on Research & Development (R&D) of Rs 7.48 crore or 16.68 per cent of the revenue for the quarter.
The results are visible in the Hyderabad-based company obtaining 13 product patents. Suven's drug discovery pipeline is also strong with molecules at various stages of trials targeting dementia, Huntington's disease, Parkinson's, Schizophrenia etc.